Evidence map›Paper›PMID 35096563›Full record

ArticleFrontiers in oncology2021

Exosomal Long Non-Coding RNA ANCR Mediates Drug Resistance in Osteosarcoma.

Xin Hu, Yang Wen, Lin-Yun Tan, Jie Wang, Fan Tang, Yi-Tian Wang, Chuan-Xi Zheng, Yu-Qi Zhang, Tao-Jun Gong, Li Min

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Exosome-mediated siRNA delivery in cancer: Loading strategies, targeting approaches, and therapeutic outcomes.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Exosomes and osteosarcoma drug resistance.Frontiers in oncology · 2023
    Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xin HuOrthopedic Research Institute, Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, China.
Yang WenOrthopedic Research Institute, Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, China.
Lin-Yun TanOrthopedic Research Institute, Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, China.
Jie WangOrthopedic Research Institute, Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, China.
Fan TangOrthopedic Research Institute, Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, China.
Yi-Tian WangOrthopedic Research Institute, Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, China.
Chuan-Xi ZhengOrthopedic Research Institute, Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, China.
Yu-Qi ZhangOrthopedic Research Institute, Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, China.
Tao-Jun GongOrthopedic Research Institute, Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, China.
Li MinOrthopedic Research Institute, Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma (OS) is rare cancer with bimodal age distribution with peaks observed in children and young adults. Typically, OS is treated with pre-surgery neoadjuvant therapy, surgical excision, and post-surgery chemotherapy. However, the efficacy of treatment on disease prognosis and objective response is not currently optimal, often resulting in drug resistance; in turn, highlighting the need to understand mechanisms driving resistance to therapy in OS patients. Using Doxycycline (Dox)-sensitive and resistant variants of OS cells lines KHOS and U2OS, we found that the resistant variants KHOS-DR and U2OS-DR have significantly higher

Indexed as

ANCRdrug resistanceexosomeslncRNAosteosarcoma

Identifiers

PMID35096563
PMCPMC8789737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.